|
|
Volumn 10, Issue 1, 2013, Pages 4-13
|
|
Legal defenses and outcomes in Paragraph IV patent litigation
|
|
Author keywords
ANDA; Hatch Waxman; Infringement; Litigation; Paragraph IV; Patent; US generic market
|
|
Indexed keywords
ADAPALENE;
AGATROBAN;
AMFEBUTAMONE;
ARGATROBAN;
ARIPIPRAZOLE;
BIMATOPROST;
BRIMONIDINE;
BRIMONIDINE PLUS TIMOLOL;
CINACALCET;
DOXERCALCIFEROL;
DOXYCYCLINE;
DULOXETINE;
ETHINYLESTRADIOL PLUS LEVONORGESTREL;
ETHINYLESTRADIOL PLUS NORGESTIMATE;
FAMCICLOVIR;
FLUINDOSTATIN;
GEMCITABINE;
GENERIC DRUG;
GLATIRAMER;
HECTORAL;
ITRACONAZOLE;
LYRICAL;
MONTELUKAST;
NORGESTIMATE;
OLMESARTAN;
OLOPATADINE;
OMEGA 3 ACID ETHYL ESTER;
PEMETREXED;
PREGABALIN;
QUETIAPINE;
ROPIVACAINE;
ROSUVASTATIN;
SALCATONIN;
SENISIPAR;
TOLTERODINE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ARTICLE;
COURT;
DECISION MAKING;
DRUG APPROVAL;
DRUG COST;
DRUG FORMULATION;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
PATENT;
UNITED STATES;
|
|
EID: 84879299994
PISSN: 17411343
EISSN: 17417090
Source Type: Journal
DOI: 10.1177/1741134313482558 Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
